SCYNEXIS, Inc. Receives FDA Fast Track and QIDP Designations for Intravenous Formulation of SCY-078 for the Treatment of Patients with Invasive Fungal Infections
January 28, 2016 09:05 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., Jan. 28, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the U.S. Food and Drug Administration (FDA) has granted both Fast...
SCYNEXIS, Inc. Initiates Enrollment of the Phase 2 Study of SCY-078 in Vulvovaginal Candidiasis
December 01, 2015 17:09 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., Dec. 1, 2015 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that it has initiated enrollment and the first group of patients have been...
SCYNEXIS, Inc. Reports Third Quarter 2015 Financial Results and Provides Company Update
November 13, 2015 09:03 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., Nov. 13, 2015 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today reported financial results for the quarter ended September 30, 2015, and provided an...
SCYNEXIS, Inc. Announces Initiation of Phase 1 Clinical Trial Evaluating Intravenous Formulation of SCY-078
November 12, 2015 08:30 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the initiation of a Phase 1 clinical trial to study the intravenous (IV)...
SCYNEXIS Appoints Eric Francois as Chief Financial Officer
November 02, 2015 17:25 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the appointment of Eric Francois as Chief Financial Officer,...
SCYNEXIS Appoints Rajeshwar Motheram as Vice President, Pharmaceutical Development
October 07, 2015 16:30 ET
|
SCYNEXIS, Inc.
- Strengthens Management Team with the Addition of Pharmaceutical Development Expertise -
- Announces Inducement Grant Under NASDAQ Rule 5635(c)(4) -
JERSEY CITY, N.J., Oct. 7, 2015 (GLOBE...
SCYNEXIS, Inc. Announces Board of Directors Transitions
September 28, 2015 16:30 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., Sept. 28, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the following changes to its Board of Directors:
Edward...
SCYNEXIS Presents Data Supporting the Potential Clinical Utility of Antifungal Drug Candidate at ICAAC/ICC 2015
September 21, 2015 08:30 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., Sept. 21, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) announced today that results of three nonclinical studies of the company's...
SCYNEXIS to Present Data at ICAAC/ICC 2015 for Novel Antifungal Drug Candidate
September 10, 2015 08:30 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., Sept. 10, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced one podium and three poster presentations related to...
SCYNEXIS, Inc. Reports Second Quarter 2015 Financial Results
August 19, 2015 18:00 ET
|
SCYNEXIS, Inc.
RESEARCH TRIANGLE PARK, N.C., Aug. 19, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today reported financial results for the second quarter of...